Hostname: page-component-745bb68f8f-l4dxg Total loading time: 0 Render date: 2025-01-26T19:08:48.380Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term Glioblastoma Multiforme Survivors: a Population-based Study

Published online by Cambridge University Press:  18 September 2015

J.N. Scott ,
N.B. Rewcastle ,
P.M.A. Brasher ,
D. Fulton ,
N.A. Hagen ,
J.A. MacKinnon ,
G. Sutherland ,
J.G. Cairncross  and
P. Forsyth
J.N. Scott
Affiliation:
Departments of Clinical Neurosciences and Pediatrics, The University of Calgary, and Department of Medicine, Foothills Hospital and Tom Baker Cancer Centre (TBCC), Calgary
N.B. Rewcastle
Affiliation:
Department of Pathology and Clinical Neurosciences, The University of Calgary, and Department of Medicine, Foothills Hospital, Calgary
P.M.A. Brasher
Affiliation:
Department of Epidemiology, Prevention and Screening, Alberta Cancer Board and Community Health Sciences, The University of Calgary, Calgary
D. Fulton
Affiliation:
Department of Radiation Oncology, Cross Cancer Institute (CCI) and Department of Medicine/Neurology, University of Alberta, Edmonton
N.A. Hagen
Affiliation:
Departments of Clinical Neurosciences and Pediatrics, The University of Calgary, and Department of Medicine, Foothills Hospital and Tom Baker Cancer Centre (TBCC), Calgary
J.A. MacKinnon
Affiliation:
Department of Radiation Oncology, Tom Baker Cancer Centre (TBCC), The University of Calgary, Calgary
G. Sutherland
Affiliation:
Departments of Clinical Neurosciences and Pediatrics, The University of Calgary, and Department of Medicine, Foothills Hospital and Tom Baker Cancer Centre (TBCC), Calgary
J.G. Cairncross
Affiliation:
Departments of Clinical Neurological Sciences and Oncology, Western Ontario and London Regional Cancer Centre, London, Ontario
P. Forsyth*
Affiliation:
Departments of Clinical Neurosciences and Pediatrics, The University of Calgary, and Department of Medicine, Foothills Hospital and Tom Baker Cancer Centre (TBCC), Calgary
*
Department of Medicine, Tom Baker Cancer Centre, 1331 - 29 Street N.W., Calgary, Alberta, Canada T2N 4N2
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Long-term glioblastoma multiforme survivors (LTGBMS) are uncommon. The frequency which these occur in an unselected population and factors which produce these unusually long survivors are unknown.

Objectives:

To determine in a population- based study 1) the frequency of LTGBMS in a population and 2) identify which patient, treatment or tumor characteristics would predict which glioblastoma (GBM) patient would become a LTGBMS.

Methods:

The Alberta Cancer Registry was used to identify all patients diagnosed with GBM in southern Alberta between 1/1/75 - 12/31/91. Patient charts were reviewed and histology re-examined by a blinded neuropathologist. LTGBMS were defined as GBM patients surviving ≥ 3 years after diagnosis. Each LTGBMS was compared to three age-, gender-, and year of diagnosis-matched controls to compare patient, treatment, and tumor factors to GBM patients without long-term survival.

Results:

There were 279 GBMs diagnosed in the study period. Five (1.8%) survived ≥ three years (range, 3.2-15.8 years). Seven additional long-term survivors, who carried a diagnosis of GBM, were excluded after neuropathologic review; the most common revised diagnosis was malignant oligodendroglioma. LTGBMS (avg. age = 45 years) were significantly younger when compared to all GBM patients (avg. age = 59 years, p - 0.0001) diagnosed in the study period. LTGBMS had a higher KPS at diagnosis (p = 0.001) compared to controls. Tumors from LTGBMS tended to have fewer mitoses and a lower Ki-67 cellular proliferative index compared to controls. Radiation-induced dementia was common and disabling in LTGBMS.

Conclusions:

These data highlight the dismal prognosis for GBM patients who have both a short median survival and very small chance (1.8%) of long-term survival. The LTGBMS were younger, had a higher performance status, and their tumors tended to proliferate less rapidly than control GBM patients. When long-term survival does occur it is often accompanied by severe treatment-induced dementia.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 25 , Issue 3 , August 1998 , pp. 197 - 201
Copyright
Copyright © Canadian Neurological Sciences Federation 1998

References

REFERENCES

1.Fine, HA. The basis for current treatment recommendations for malignant gliomas. J Neuro-Oncol 1994; 20: 111–120.Google ScholarPubMed
2.Forsyth, PA, Cairncross, JG. Treatment of malignant glioma in adults. Curr Opin Neurol 1995; 8: 414–418.CrossRefGoogle ScholarPubMed
3.Kepes, JJ, Rubinstein, LJ, Eng, LF. Pleomorphic xanthoastrocytoma: a distinctive meningocerebral glioma of young subjects with relatively favorable prognosis. Cancer 1979; 44: 1839–1852.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
4.Daumas-Duport, C, Scheithauer, B, O’Fallon, J, Kelly, P. Grading of astrocytomas: a simple and reproducible method. Cancer 1988; 62: 2152–2165.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
5.Balmaceda, C, Goldman, J, Fetell, MR. Long-term survival in malignant astrocytomas re-evaluated: are they really oligodendrogliomas? Neurology 1996; 46(2): A451 (Abstr).Google Scholar
6.Elvidge, AR, Barone, BM. Long-term postoperative survival in two cases of glioblastoma multiforme. J Neurosurg 1965; 22: 382–386.CrossRefGoogle ScholarPubMed
7.Müller, H, Brock, M, Ernst, H. Long-term survival and recurrence-free interval in combined surgical, radio- and chemotherapy of malignant brain gliomas. Clin Neurol Neurosurg 1985; 87(3): 167–171.CrossRefGoogle ScholarPubMed
8.Imperato, JP, Paleologos, NA, Vick, NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 1990; 28: 818–822.CrossRefGoogle ScholarPubMed
9.Ullén, H, Mattsson, B, Collins, VP. Long-term survival after malignant glioma: a clinical and histopathological study on the accuracy of the diagnosis in a population-based cancer registry. Acta Oncol 1990; 29: 875–878.CrossRefGoogle Scholar
10.Vertosick, FT, Selker, RG. Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 1992; 38: 359–363.CrossRefGoogle ScholarPubMed
11.Chandler, KL, Prados, MD, Malec, M, Wilson, CB. Long-term survival in patients with glioblastoma multiforme. Neurosurgery 1993; 32(5): 716–720.CrossRefGoogle ScholarPubMed
12.Salcman, M, Scholtz, H, Kaplan, RS, Kulik, S. Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994; 34(2): 213–220.CrossRefGoogle ScholarPubMed
13.Morita, M, Rosenblum, MK, Bilsky, MH, Fraser, RAR, Rosenfeld, MR. Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neuro-Oncol 1996; 27: 259–266.CrossRefGoogle ScholarPubMed
14.Olivera, C, Bartley, M, Ferrall, S, Phuphanich, S. Long-term malignant glioma survivors over ten years: prognostic factors. Proceedings of ASCO 1997; 16: 407a (Abstr).Google Scholar
15.Forsyth, PA, Shaw, E, Scheithauer, B, Layton, D, O’Fallon, J. 51 Cases of supratentorial pilocytic astrocytoma: a clinicopathologic, prognostic, and flow-cytometric study. Cancer 1993; 72: 1335–1342.3.0.CO;2-E>CrossRefGoogle Scholar
16.Byar, DP, Green, SB, Strike, TA, et al. Prognostic factors for malignant glioma. In: Walker, MD, ed. Oncology of the Nervous System. Boston: Marinus Nijhoff, 1983: 379–395.CrossRefGoogle Scholar
17.Jaros, E, Perry, R, Adam, L, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors. Br J Cancer 1992; 66: 373–385.CrossRefGoogle Scholar
18.Dorward, NL, Hawkins, RA, Whittle, IR. Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma. Br J Neurosurg 1993; 7: 197–199.CrossRefGoogle ScholarPubMed
19.Pigott, TJ, Robson, DK, Palmer, J, Ward, LM. Expression of epidermal growth factor receptor in human glioblastoma multiforme. Br J Neurosurg 1993; 7: 261–265.CrossRefGoogle ScholarPubMed
20.Fine, HA, Dear, KBG. Loeffler, JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585–2597.3.0.CO;2-S>CrossRefGoogle ScholarPubMed
21.Walker, MD, Green, SB, Byar, DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323–1329.CrossRefGoogle ScholarPubMed
22.Archibald, YM, Lunn, D, Ruttan, LA, et al. Cognitive functioning in long-term survivors of high grade glioma. J Neurosurg 1994; 80: 247–253.CrossRefGoogle ScholarPubMed
23.Salford, L, Brun, A, Nirfalk, S. Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 1988; 69: 506–509.CrossRefGoogle ScholarPubMed
24.Cairncross, JG, Macdonald, DR, Ludwin, S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013–2021.CrossRefGoogle ScholarPubMed